Press release Ecully,
First-quarter 2024 revenue of €3.1 million
Growth of 28% compared with 2023 first quarter
In thousands of euros | 2024 | 2023 | Change 2023/2022 |
Q1 revenue | 3,070 | 2,398 | +28% |
Unaudited consolidated data
This purely organic growth (with no scope effect) reflects the Group’s strong sales momentum in its two main regions,
Over the period, sales in
The positive revenue trend for the first quarter of 2024 confirms Spineway’s ability to gain market share and grow in an increasingly demanding environment. This sales growth will enable the Group to continue its investments to obtain new approvals and CE/MDR certifications for its product ranges. The Group confirms its aim of becoming a major player in less invasive spine treatments.
Next event:
SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
ISIN: FR001400BVK2 – ALSPW
Contacts:
SPINEWAY GROUP Shareholder-services line Available Tuesday through Thursday +33 (0)806 706 060 | Eligible PEA / PME ALSPW Euronext Growth | AELIUM Finance & Communication Investor relations spineway@aelium.fr |
Attachment
- CP_SPW-CAT12024_VDEF_EN
© OMX, source